Concurrent diabetes and obesity commonly occur; improving long-term metabolic control with diabetes treatments and interventions that contribute to weight loss/neutrality is imperative to the management of diabesity worldwide
‘Diabesity’ – interlinking treatments to improve outcomes in diabetes and obesity
Printable Q&A for Offline SubmissionQuiz-summary
0 of 15 questions completed
Questions:
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
Information
You have already completed the module before. Hence you can not start it again.
Module is loading…
You have to finish following quiz, to start this quiz:
Results
Results
Time has elapsed
Categories
- Not categorized 0%
-
Thank you, we will review your submission and notify you of your results via email.
If not received within 5 hours due to spam, don’t worry, it will show in your profile.
Did you ensure your names and HPCSA/council numbers are correct for the certificate?
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- Answered
- Review
- Question 1 of 15
1. Question
1. Obesity is associated with more than __ comorbidities:
- Question 2 of 15
2. Question
2. Both obesity and diabetes are characterised by insulin resistance and insulin deficiency:
- Question 3 of 15
3. Question
3. Which statement is true?
- Question 4 of 15
4. Question
4. Diabetes prevention studies have shown that in pre-diabetic individuals, intensive lifestyle intervention decreases overall risk/incidence of T2DM by ___:
- Question 5 of 15
5. Question
5. In respect of metabolic profile, physical activity has been shown to improve:
- Question 6 of 15
6. Question
6. Which of the following anti-obesity drugs can only be used short term due to significant risks?
- Question 7 of 15
7. Question
7. The most effective treatment option for patients with diabesity is:
- Question 8 of 15
8. Question
8. Which statement best describes the weight effect of metformin use?
- Question 9 of 15
9. Question
9. Of the following GLP-1 RAs, which is registered for use as an anti-obesity treatment in patients without diabetes?
- Question 10 of 15
10. Question
10. Of the following GLP-1 RAs, which has not shown cardiovascular benefit?
- Question 11 of 15
11. Question
11. Renoprotective benefits are most associated with which class of antidiabetic drugs?
- Question 12 of 15
12. Question
12. DPP-4 inhibitors are associated with significant weight gain:
- Question 13 of 15
13. Question
13. Which statement is true? Thiazolidinediones are associated with:
- Question 14 of 15
14. Question
14. Which of the following sulphonylureas is recommended for use by SEMDSA and associated with minimal weight gain?
- Question 15 of 15
15. Question
15. For patients with obesity and T2DM requiring insulin therapy, the Endocrine Society Clinical Practice Guideline recommends concomitantly prescribing at least one weight loss-promoting medication to mitigate weight gain associated with insulin use:
Do you like this? Share with a colleague
[DISPLAY_ULTIMATE_SOCIAL_ICONS]